BACKGROUND: Cognitive impairment has long been recognized as a manifestation of human immunodeficiency virus (HIV) infection. However, highly active antiretroviral therapy (HAART) has altered the neurologic manifestations of HIV. OBJECTIVES: To develop a measure to quantify the motor abnormalities included in the original descriptions of HIV-associated dementia (HAD); to determine whether motor, affective, and behavioral dysfunction predict cognitive impairment; and to determine whether quantitative motor testing is a helpful adjunct in the diagnosis of HAD in a complex population from the HAART era. DESIGN: Neurologic and neuropsychological data were collected from the Manhattan HIV Brain Bank, a longitudinal cohort study of patients with advanced HIV. The HIV-Dementia Motor Scale (HDMS) was developed and validated and cognitive and affective or behavioral function was quantified using global neuropsychological T scores, the Beck Depression Inventory (BDI), and an independent assessment of apathy. Relationships among cognitive, motor, affective, and behavioral performance were examined using correlation, linear regression, and analyses of variance. SETTING: An urban AIDS research center. PARTICIPANTS: A total of 260 HIV-positive, predominantly minority patients. MAIN OUTCOME MEASURES: The HDMS scores and global neuropsychological T scores. RESULTS: The HDMS and BDI scores were independent predictors of cognitive impairment. Significant cognitive impairment was found in patients with motor dysfunction. Patients diagnosed as having HAD had a greater degree of motor impairment than those with other neurocognitive diagnoses. CONCLUSIONS: Motor, affective, and behavioral abnormalities predict cognitive impairment in HIV-positive patients in this HAART-era cohort. The HDMS may be useful in the assignment of HIV-associated neurocognitive impairment in HIV populations in which normative data or neuropsychological test design is not optimal.
BACKGROUND:Cognitive impairment has long been recognized as a manifestation of human immunodeficiency virus (HIV) infection. However, highly active antiretroviral therapy (HAART) has altered the neurologic manifestations of HIV. OBJECTIVES: To develop a measure to quantify the motor abnormalities included in the original descriptions of HIV-associated dementia (HAD); to determine whether motor, affective, and behavioral dysfunction predict cognitive impairment; and to determine whether quantitative motor testing is a helpful adjunct in the diagnosis of HAD in a complex population from the HAART era. DESIGN: Neurologic and neuropsychological data were collected from the Manhattan HIV Brain Bank, a longitudinal cohort study of patients with advanced HIV. The HIV-Dementia Motor Scale (HDMS) was developed and validated and cognitive and affective or behavioral function was quantified using global neuropsychological T scores, the Beck Depression Inventory (BDI), and an independent assessment of apathy. Relationships among cognitive, motor, affective, and behavioral performance were examined using correlation, linear regression, and analyses of variance. SETTING: An urban AIDS research center. PARTICIPANTS: A total of 260 HIV-positive, predominantly minority patients. MAIN OUTCOME MEASURES: The HDMS scores and global neuropsychological T scores. RESULTS: The HDMS and BDI scores were independent predictors of cognitive impairment. Significant cognitive impairment was found in patients with motor dysfunction. Patients diagnosed as having HADhad a greater degree of motor impairment than those with other neurocognitive diagnoses. CONCLUSIONS: Motor, affective, and behavioral abnormalities predict cognitive impairment in HIV-positivepatients in this HAART-era cohort. The HDMS may be useful in the assignment of HIV-associated neurocognitive impairment in HIV populations in which normative data or neuropsychological test design is not optimal.
Authors: Catherine L Carey; Steven Paul Woods; Julie D Rippeth; Raul Gonzalez; David J Moore; Thomas D Marcotte; Igor Grant; Robert K Heaton Journal: Clin Neuropsychol Date: 2004-05 Impact factor: 3.535
Authors: A Antinori; G Arendt; J T Becker; B J Brew; D A Byrd; M Cherner; D B Clifford; P Cinque; L G Epstein; K Goodkin; M Gisslen; I Grant; R K Heaton; J Joseph; K Marder; C M Marra; J C McArthur; M Nunn; R W Price; L Pulliam; K R Robertson; N Sacktor; V Valcour; V E Wojna Journal: Neurology Date: 2007-10-03 Impact factor: 9.910
Authors: Justin C McArthur; Michael P McDermott; Daniel McClernon; Coryse St Hillaire; Kathy Conant; Karen Marder; Giovanni Schifitto; Ola A Selnes; Ned Sacktor; Yaakov Stern; Steve M Albert; Karl Kieburtz; Joy A deMarcaida; Bruce Cohen; Leon G Epstein Journal: Arch Neurol Date: 2004-11
Authors: J C McArthur; D R McClernon; M F Cronin; T E Nance-Sproson; A J Saah; M St Clair; E R Lanier Journal: Ann Neurol Date: 1997-11 Impact factor: 10.422
Authors: Elizabeth L Ryan; Reon Baird; Monica Rivera Mindt; Desiree Byrd; Jennifer Monzones; Susan Morgello Bank Journal: J Int Neuropsychol Soc Date: 2005-11 Impact factor: 2.892
Authors: Rujvi Kamat; Erin Morgan; Thomas D Marcotte; Jayraan Badiee; Ingrid Maich; Mariana Cherner; Sergio de Almeida; Ana Paula de Pereira; Clea Elisa Ribeiro; Francisco Barbosa; J Hamp Atkinson; Ronald Ellis Journal: J Affect Disord Date: 2012-12-11 Impact factor: 4.839